CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Arrowhead Signs Deal With Madrigal to License Clinical MASH Program

Positive
AI Analysis

Summary

Arrowhead has signed a licensing deal with Madrigal for a clinical MASH program. The agreement represents a partnership to advance a clinical-stage metabolic dysfunction-associated fatty liver disease candidate.

Importance:6/10
Sentiment:
0.50
licensingMASHclinical_program
Related Companies

Read the original article

Published by yahoo_finance on May 5, 2026 2:37 PM

Read Original